Emami Hamid, Shakeri Ali Asghar, Akhavan Ali, Shahbazi-Gahrouei Daryoush, Akbari Pouya
Department of Radiation Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Med Sci. 2018 Dec 28;23:111. doi: 10.4103/jrms.JRMS_793_17. eCollection 2018.
The aim of this study was to determine the effect of Livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen.
This was an add-on nonrandomized clinical trial study on thirty selected eligible cancer patients undergoing irinotecan (8 patients) and oxaliplatin (22 patients) with diagnosed fatty liver disease-based liver ultrasonography, as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Patients in each group received Livergol at a dose of 140 mg daily for 1 month. ALT and AST levels as well as grade of fatty liver were evaluated before and after intervention.
In the oxaliplatin/Livergol group, 40% and 44.4% of patients who were in Grade 2 and 3 before intervention were altered to Grades 1 and 2, respectively ( = 0.005), and in irinotecan/Livergol group, the mentioned percentages were 80% and 66.7% ( = 0.014). The mean levels of ALT and AST enzymes were decreased in both groups after tacking Livergol; however, the observed decreases were not significantly different between groups.
It was concluded that the adding of Livergol to oxaliplatin and irinotecan regimens significantly improved the fatty liver of patients and none of them was superior.
本研究旨在确定利维肝对接受基于伊立替康和奥沙利铂化疗方案的癌症患者脂肪肝改善情况的影响。
这是一项附加的非随机临床试验研究，选取了30例符合条件的癌症患者，这些患者经肝脏超声检查以及丙氨酸氨基转移酶（ALT）和天冬氨酸氨基转移酶（AST）诊断为脂肪肝，其中8例接受伊立替康治疗，22例接受奥沙利铂治疗。每组患者每天服用140毫克利维肝，持续1个月。在干预前后评估ALT和AST水平以及脂肪肝等级。
在奥沙利铂/利维肝组中，干预前2级和3级的患者分别有40%和44.4%转变为1级和2级（P = 0.005），在伊立替康/利维肝组中，上述百分比分别为80%和66.7%（P = 0.014）。两组服用利维肝后ALT和AST酶的平均水平均下降；然而，两组观察到的下降没有显著差异。
得出的结论是，在奥沙利铂和伊立替康方案中添加利维肝可显著改善患者的脂肪肝，且两者效果无优劣之分。
